Berotralstat, sold under the brand name Orladeyo, is a medication used to prevent attacks of hereditary angioedema (HAE) in people aged twelve years and older.

[4] Berotralstat was approved for medical use in the United States in December 2020,[3][4][9] and in the European Union in April 2021.

[4] The trial was conducted at 40 sites in the United States, the European Union, and Canada.

[4] Participants were assigned to receive one of two doses of berotralstat or placebo once every day for 24 weeks.

[4] Neither the participants nor the investigators knew which treatment was being given until after the trial was completed.